Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids

Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.

Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab

An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY

Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.

Nalak Das headshot

Top 5 Low-Beta High-Yielding Stocks to Counter Volatility

We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, PKG, ATO, TXN and CCI.

Zacks.com featured highlights include Crocs, Sonic Automotive, Pfizer, ExxonMobil and KB Home

Crocs, Sonic Automotive, Pfizer, ExxonMobil and KB Home are included in this blog.

TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates

Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.

AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales

AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance

Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales

Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.

Rimmi Singhi headshot

Boost Your Returns With These 5 High Earnings Yield Stocks

Crocs (CROX), Sonic Automotive (SAH), Pfizer (PFE), ExxonMobil (XOM) and KB Home (KBH) are some top-ranked stocks boasting high earnings yield.

Best Growth Stocks to Buy for February 9th

AAPL, PFE, and APA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 9, 2022

The Zacks Analyst Blog Highlights Amgen, TakeTwo Interactive, Chegg, Pfizer and BP

Amgen, TakeTwo Interactive, Chegg, Pfizer and BP are included in this blog.

Best Growth Stocks to Buy for February 8th

CROX, PFE, and CLS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 8, 2022

Markets Await More Earnings Data

Markets Await More Earnings Data

Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down

Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.

Mark Vickery headshot

NVIDIA/ARM Deal Off, Peloton CEO Steps Down

Tech giant NVIDIA's (NVDA) planned acquisition of Softbank entity Arm Software is no more.

Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall

Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.

Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?

Smart Beta ETF report for DIV

Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?

Smart Beta ETF report for USMC

Mark Vickery headshot

Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat

After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.

Daniel Laboe headshot

The Markets' Tone: Cautiously Optimistic

As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds

Best Growth Stocks to Buy for February 7th

AAPL, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 7, 2022

Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer

AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.

How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Sundeep Ganoria  headshot

Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH

Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.